Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;49(10):10101-10113.
doi: 10.1007/s11033-022-07594-9. Epub 2022 Jun 3.

Demethyleneberberine, a potential therapeutic agent in neurodegenerative disorders: a proposed mechanistic insight

Priyanka Saklani  1 , Heena Khan  1 , Thakur Gurjeet Singh  2 , Saurabh Gupta  1 , Amarjot Kaur Grewal  1
Affiliations

Demethyleneberberine, a potential therapeutic agent in neurodegenerative disorders: a proposed mechanistic insight

Priyanka Saklani et al. Mol Biol Rep. 2022 Oct.

Abstract

Introduction: Neurodegenerative disorders are a diverse variety of diseases that can be distinguished from developing degeneration of neurons in the CNS. Several alkaloids have shown mounting effects in neurodegenerative disorders, and berberine is one of them. Demethyleneberberine is a metabolite of berberine that has better blood-brain barrier crossing capacity. Demethyleneberberine possesses anti-inflammatory, anti-oxidant, and mitochondrial targeting properties. However, neither the pharmacological action nor the molecular mechanism of action of demethyleneberberine on neurodegenerative disorders has been explored yet.

Materials and methods: A systematic literature review of PubMed, Medline, Bentham, Scopus, and EMBASE (Elseveier) databases was carried out with the help of keywords like "Demethyleneberberine; neuroinflammation; oxidative stress; Neuroprotective; Neurodegenerative disorders" till date.

Conclusion: This review focus on the neuroprotective potential of demethyleneberberine in neurodegenerative disorders by attenuating different pathways, i.e., NF-κB, MAPK, and AMPK signalling.

Keywords: Demethyleneberberine; Neurodegenerative disorders; Neuroinflammation; Neuroprotective; Oxidative stress.

PubMed Disclaimer

References

    1. Tiwari P, Khan H, Singh TG, Grewal AK (2022) Poly (ADP-ribose) polymerase: an overview of mechanistic approaches and therapeutic opportunities in the management of stroke. Neurochem Res 18:1–23. https://doi.org/10.1007/s11064-022-03595-z - DOI
    1. Khan H, Garg N, Singh TG, Kaur A, Thapa K (2022) Calpain inhibitors as potential therapeutic modulators in neurodegenerative diseases. Neurochem Res 4:1–25. https://doi.org/10.1007/s11064-021-03521-9 - DOI
    1. Sun AY, Wang Q, Simonyi A, Sun GY (2008) Botanical phenolics and brain health. Neuromol Med 10:259–274. https://doi.org/10.1007/s12017-008-8052-z - DOI
    1. Hussain G, Rasul A, Anwar H, Aziz N, Razzaq A, Wei W, Ali M, Li J, Li X (2018) Role of plant derived alkaloids and their mechanism in neurodegenerative disorders. Int J Biol Sci 14:341. https://doi.org/10.7150/ijbs.23247 - DOI - PubMed - PMC
    1. Strain JJ, Karim A, Caliendo G, Brodsky M, Lowe RS III, Himelein C (2003) Neurologic drug–psychotropic drug update. Dis Mon 49:326–371. https://doi.org/10.1067/mda.2003.25 - DOI

Publication types

MeSH terms

LinkOut - more resources